Drug Profile
BI 44847
Alternative Names: BI44847Latest Information Update: 01 Oct 2014
Price :
$50
*
At a glance
- Originator Ajinomoto
- Developer Boehringer Ingelheim
- Class
- Mechanism of Action Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 30 Sep 2014 Discontinued - Phase-I for Type-2 diabetes mellitus (In volunteers) in Germany (PO, Suspension, Liquid, Tablet) (NCT02211937)
- 30 Sep 2014 Discontinued - Phase-I for Type-2 diabetes mellitus (In volunteers) in Germany (PO, Powder) (NCT02209844)
- 30 Sep 2014 Discontinued - Phase-I for Type-2 diabetes mellitus (In volunteers) in Japan (PO) (NCT02211924)